FDA Tightens Grip On Safe Weight Loss Drugs, WHO Adds Them To Essential Medicines List

FDA, HHS Shift Vaccine Strategy

The U.S. Food and Drug Administration on Friday established a "green list" import alert to help stop potentially dangerous GLP-1 (glucagon-like peptide-1) active pharmaceutical ingredients (APIs) from unverified foreign sources from entering the U.S. market.

Certain GLP-1 drugs, including Novo Nordisk A/S’ (NYSE:NVO) semaglutide and Eli Lilly and Co.’s (NYSE:LLY) tirzepatide, are FDA-approved for specific uses such as treating type 2 diabetes and, in certain cases, chronic weight management.